Roberto Borea, Research Assistant Professor at Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, shared on LinkedIn:
“I am honored to share our latest commentary published in International Lung Cancer News (ILCN) on ctDNA-guided adaptive de-escalation therapy for advanced NSCLC.
It was a privilege to co-author this piece with Christian Rolfo, discussing the opportunities and challenges of using liquid biopsy to guide treatment adaptation in precision oncology.”
Title: ctDNA-Guided Adaptive De-escalation Therapy for Advanced NSCLC: Ready for Prime Time?
Authors: Christian Rolfo and Roberto Borea
Read the full article.
This can be interesting:
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
